Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
Goldman Sachs & Co. LLC and
A registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with the
The offering will be made only by means of a prospectus. A preliminary prospectus supplement describing the terms of the offering has been filed with the
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-pricing-of-public-offering-of-shares-of-common-stock-300991858.html
SOURCE
Investor and Media Contact, Jim Baker, 617-844-8236, media@blueprintmedicines.com; Investor Contact, Kristin Hodous, 617-714-6674, ir@blueprintmedicines.com